Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

(2020) S. Popat et al.   ANNALS OF ONCOLOGY

ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

(2020) P. Baas et al.   Journal of Thoracic Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

(2019) Arnaud Scherpereel et al.   LANCET ONCOLOGY

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

(2019) Maria J Disselhorst et al.   Lancet Respiratory Medicine

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma

(2019) Raffit Hassan et al.   JAMA Oncology

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays

(2019) David B. Chapel et al.   HUMAN PATHOLOGY

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

(2019) Giorgio V Scagliotti et al.   Lancet Respiratory Medicine

Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)

(2019) Morihito Okada et al.   CLINICAL CANCER RESEARCH

Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications

(2018) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma

(2018) Josine Quispel-Janssen et al.   Journal of Thoracic Oncology

A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma

(2018) Fausto Petrelli et al.   RESPIRATORY MEDICINE

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

(2018) Luana Calabrò et al.   Lancet Respiratory Medicine

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

(2018) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

(2017) Evan W Alley et al.   LANCET ONCOLOGY

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

(2016) Gérard Zalcman et al.   LANCET

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) P. Baas et al.   ANNALS OF ONCOLOGY

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

(2015) Susana Cedrés et al.   PLoS One

B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis

(2014) Aaron Scott Mansfield et al.   Journal of Thoracic Oncology

Randomized Phase II Trials: Time for a New Era in Clinical Trial Design

(2010) Sumithra J. Mandrekar et al.   Journal of Thoracic Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER